Price$6.91-0.30 (-4.23%)
01:30 PM07:45 PM
News · 26 weeks540%
2026-01-182026-07-12
Mix3190d
- Insider15(48%)
- Other7(23%)
- SEC Filings6(19%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- INSIDERNew insider Mohammed Faiz claimed ownership of 163,686 shares (SEC Form 3)3 - Certara, Inc. (0001827090) (Issuer)
- PRCertara to Report Second Quarter 2026 Financial Results on August 4th, 2026RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara transforms drug discovery and devel
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Certara Inc.SCHEDULE 13G/A - Certara, Inc. (0001827090) (Subject)
- PRCertara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent ToolkitRADNOR, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform, unifying its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks. The NVIDIA BioNeMo Agent Toolkit turns any AI agent into an autonomous life sciences scientist, providing access to NVIDIA’s full life science stack. Within Certara's platform, BioNeMo Agent Toolkit serves as one of several agentic frameworks available to clients, working alongside Certara's biosimulation models, regulatory expertise, and scientific teams to accelerate insig
- PRThe Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in ParallelA wave of government funding, hardware progress, and looming encryption deadlines has turned quantum from a lab curiosity into one of the most closely watched corners of the market in 2026, spanning computing hardware and the cybersecurity built to survive it.VANCOUVER, BC, July 6, 2026 /CNW/ -- USA News Group News Commentary, For years, quantum computing lived mostly in research papers and conference keynotes. In 2026 it has become something harder to ignore: a sector with federal capital behind it, a string of technical milestones on the board, and a parallel race to rebuild the world's encryption before quantum machines can break it. The result is one of the most polarizing themes in the
- SECCertara Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Certara, Inc. (0001827090) (Filer)
- PRCertara Announces CFO TransitionRADNOR, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, announces that John Gallagher, Chief Financial Officer, has notified the Company of his intent to resign from his office effective as of the end of the day on July 14, 2026. Concurrently, Certara has launched a search with a leading executive search firm to identify the Company's next Chief Financial Officer. Faiz Mohammed, Certara's Senior Vice President of Finance and Treasurer, has agreed to serve as Interim CFO upon Mr. Gallagher's departure until a successor is named and appointed. Mr. Mohammed has been a finance leader with Certara since 2018 and brings mo
- PRThe Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItIssued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually
- INSIDERChief Human Resources Officer Anhalt Rona converted options into 7,147 shares and covered exercise/tax liability with 2,241 shares, increasing direct ownership by 41% to 16,789 units (SEC Form 4) (withholding tax)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSVP and General Counsel Corcoran Daniel converted options into 22,830 shares and covered exercise/tax liability with 12,103 shares, increasing direct ownership by 50% to 32,046 units (SEC Form 4) (for tax liability)4 - Certara, Inc. (0001827090) (Issuer)
- PRCertara to Participate in Upcoming Investor ConferencesRADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: RBC CM Global Healthcare ConferenceDate and Time: Tuesday, May 19 at 9:30 a.m. ET William Blair's 46th Annual Growth Stock ConferenceDate: Tuesday, June 2 Jefferies Global Healthcare ConferenceDate: Wednesday, June 3 at 1:20 p.m. ET Live webcasts for the RBC and Jefferies conferences will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About CertaraCertara accelerates me
- SECSEC Form 8-K filed by Certara Inc.8-K - Certara, Inc. (0001827090) (Filer)
- INSIDERDirector Bedi Arjun converted options into 5,547 shares (SEC Form 4)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERChairman Broshy Eran converted options into 15,757 shares, increasing direct ownership by 45% to 50,708 units (SEC Form 4)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERChief Financial Officer Reynders John V W converted options into 15,757 shares, increasing direct ownership by 147% to 26,466 units (SEC Form 4)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by Certara Inc.4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERDirector Killefer Nancy converted options into 15,757 shares, increasing direct ownership by 44% to 51,846 units (SEC Form 4)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERChairman Cashman James E Iii converted options into 15,757 shares, increasing direct ownership by 3% to 484,197 units (SEC Form 4)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT, PREDICTIVE TECH Aspbury Robert4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT, CHIEF COMMERCAL OFF Pedersen Leif E4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by Chief Human Resources Officer Anhalt Rona4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERChief Executive Officer Resnick Jon Matthew converted options into 59,766 shares and covered exercise/tax liability with 24,377 shares (SEC Form 4) (withholding tax)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by SVP and General Counsel Corcoran Daniel4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Gallagher John E4 - Certara, Inc. (0001827090) (Issuer)
- SECSEC Form 10-Q filed by Certara Inc.10-Q - Certara, Inc. (0001827090) (Filer)
CERT FAQ
7 questionsWhat does Certara Inc. do?
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and...Where does CERT stock trade?
Certara Inc. (CERT) is listed on NASDAQ.What sector and industry is CERT in?
Certara Inc. operates in the Technology sector, Computer Software: Prepackaged Software industry.When did Certara Inc. go public?
Certara Inc. (CERT) completed its IPO in 2020.What are analysts saying about CERT?
Certara Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight with a $800.00 price target on 2026-03-06. Recent price targets range from $800.00 to $1600.00.What companies are similar to CERT?
Notable peers in the same industry include MSFT (Microsoft Corporation), ORCL (Oracle Corporation), CRWD (CrowdStrike Holdings Inc.), SAP (SAP SE), CRM (Salesforce Inc.). Compare CERT side-by-side with any of them on Quantisnow.How can I track CERT on Quantisnow?
Quantisnow aggregates Certara Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CERT to receive live email and push alerts on every new disclosure.